This Stock Could Double After Earnings, Analysts Say

Jefferies started EVLO stock with a "buy" rating and $18 price target

Apr 30, 2019 at 10:12 AM
facebook twitter linkedin

Evelo Biosciences Inc (NASDAQ:EVLO) will report quarterly earnings on Thursday, May 2. Ahead of the event, analysts at Jefferies initiated coverage of the biotech stock with a "buy" rating and $18 price target -- more than double EVLO's closing price of $8.44 yesterday. Due to Evelo's "strong platform and promising data to date," the brokerage firm named Evelo stock its top pick for microbiome-based therapies.

As a result, EVLO shares are up 0.3% at $8.45 today. The stock has rebounded off its March low of $6.73, but has subsequently struggled to conquer its 40-day moving average. However, the $8 level -- which represents half of EVLO's May 2018 initial public offering (IPO) price of $16 -- has emerged as support in recent weeks. A move to the $18 level would mark a record high for the biotech.

Despite its recent struggles on the charts, most analysts are already in the bulls' corner. EVLO sports four "buy" ratings and only one "hold" endorsement, with not a "sell" rating in sight. Plus, the consensus 12-month price target of $22 represents expected upside of roughly 160% from the equity's current perch.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners